Patient Risk Evaluation for Transcatheter Aortic Valve Replacement (PRE-TAVR) – Predictors of Short- and Long-term Mortality to Optimize Patient Selection, Management, and Outcome

Patient Risk Evaluation for Transcatheter Aortic Valve Replacement (PRE-TAVR) – Predictors of Short- and Long-term Mortality to Optimize Patient Selection, Management, and Outcome - PRE-TAVR trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035463

Enrollment

2300

Registered

2024-11-11

Start date

2023-08-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aortic valve stenosis

Interventions

Group 1: TAVI patients – retrospective analysis of treatment results

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: patients with severe aortic stenosis who underwent TAVR implantation

Exclusion criteria

Exclusion criteria: incomplete data sets

Design outcomes

Primary

Measure	Time frame
Short-term (30-day) mortality after TAVR and Long-term (1-year) mortality after TAVR	—

Secondary

Measure	Time frame
1. Identification of significant predictors of short- and long-term mortality, including demographic factors, comorbidities and pre- and post-procedural parameters. 2. Comparison of the prognostic accuracy of the PRE-TAVR model with established risk scores, in particular EuroSCORE II. 3. Analysis of peri-interventional complications (e.g. renal failure, cardiopulmonary resuscitation, prolonged vasopressor therapy) and their influence on 30-day and 1-year mortality.	—

Measure

Time frame

1. Identification of significant predictors of short- and long-term mortality, including demographic factors, comorbidities and pre- and post-procedural parameters. 2. Comparison of the prognostic accuracy of the PRE-TAVR model with established risk scores, in particular EuroSCORE II. 3. Analysis of peri-interventional complications (e.g. renal failure, cardiopulmonary resuscitation, prolonged vasopressor therapy) and their influence on 30-day and 1-year mortality.

—

Countries

Germany

Contacts

Public ContactJulian Kreutz

Universitätsklinikum Marburg

kreutzj@staff.uni-marburg.de+49 64215864221

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026